NCT01918254 2017-09-12A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 ProteinHoffmann-La RochePhase 1 Completed66 enrolled